Abstract:Parkinson's disease (PD) is the second most common cause of neurodegeneration. Over the last two decades, various hypotheses have been proposed to explain the etiology of PD. Among these is the oxidant-antioxidant theory, which asserts that local and systemic oxidative damage triggered by reactive oxygen species and other free radicals may promote dopaminergic neuron degeneration. Excessive reactive oxygen species formation, one of the underlying causes of pathology in the course of PD has been evidenced by various studies showing that oxidized macromolecules including lipids, proteins, and nucleic acids accumulate in brain tissues of PD patients. DNA oxidation may produce various lesions in the course of PD. Mutations incurred as a result of DNA oxidation may further enhance reactive oxygen species production in the brains of PD patients, exacerbating neuronal loss due to defects in the mitochondrial electron transport chain, antioxidant depletion, and exposure to toxic oxidized dopamine. The protein products of SNCA, PRKN, PINK1, DJ1, and LRRK2 genes are associated with disrupted oxidoreductive homeostasis in PD. SNCA is the first gene linked with familial PD and is currently known to be affected by six mutations correlated with the disorder: A53T, A30P, E46K, G51D, H50Q and A53E. PRKN encodes Parkin, an E3 ubiquitin ligase which mediates the proteasome degradation of redundant and disordered proteins such as glycosylated α-synuclein. Over 100 mutations have been found among the 12 exons of PRKN. PINK1, a mitochondrial kinase highly expressed in the brain, may undergo loss of function mutations which constitute approximately 1–8% of early onset PD cases. More than 50 PD-promoting mutations have been found in PINK1. Mutations in DJ-1, a neuroprotective protein, are a rare cause of early onset PD and constitute only 1% of cases. Around 20 mutations have been found in DJ1 among PD patients thus far. Mutations in the LRRK2 gene are the most common known cause of familial autosomal dominant PD and sporadic PD. Treatment of PD patients, especially in the advanced stages of the disease, is very difficult. The first step in managing progressive PD is to optimize dopaminergic therapy by increasing the doses of dopamine agonists and L-dopa. The next step is the introduction of advanced therapies, such as deep brain stimulation. Genetic factors may influence the response to L-dopa and deep brain stimulation therapy and the regulation of oxidative stress. Consequently, research into minimally invasive surgical interventions, as well as therapies that target the underlying etiology of PD is warranted.

Exercise-Induced Autophagy and Parkinson’s Disease

The Mechanisms of Traditional Chinese Medicine Underlying the Prevention and Treatment of Parkinson's Disease

Deconvoluting the complexity of autophagy and Parkinson's disease for potential therapeutic purpose

Parkinson’s disease: etiopathogenesis and treatment

Exercise-Induced Neuroprotection of the Nigrostriatal Dopamine System in Parkinson's Disease.

Exercise intervention improves motor symptoms of Parkinson disease and underlying mechanisms

Oxidative stress factors in Parkinson’s disease

Biology of Parkinson's disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder

Parkinson’s Disease: From Pathogenesis to Pharmacogenomics

Potentials of autophagy enhancing natural products in the treatment of Parkinson disease

Signaling Pathways in Parkinson’s Disease: Molecular Mechanisms and Therapeutic Interventions

Targeting autophagy using small-molecule compounds to improve potential therapy of Parkinson's disease

Exercise for People with Parkinson's Disease: Updates and Future Considerations

Advances in clinical basic research: Performance, treatments, and mechanisms of Parkinson disease

Exercise sustains motor function in Parkinson's disease: Evidence from 109 randomized controlled trials on over 4,600 patients

Parkinson's Disease and the Environment

The autophagy-lysosome pathway: a potential target in the chemical and gene therapeutic strategies for Parkinson’s disease

Parkinson's disease: From genetics to molecular dysfunction and targeted therapeutic approaches

The gastrointestinal tract and Parkinson's disease

Advances in the anti-Parkinson's disease drugs

The Potential Role of Glucose Metabolism, Lipid Metabolism, and Amino Acid Metabolism in the Treatment of Parkinson's Disease.